skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8129

Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients

Review

(3142) Views  (678) Full article downloads

Authors: P Dalal, G Shah, D Chhabra, et al

Published Date August 2010 Volume 2010:3 Pages 107 - 115
DOI: http://dx.doi.org/10.2147/IJNRD.S7044

P Dalal1, G Shah1, D Chhabra2, Lorenzo Gallon2

1Department of Medicine, Mount Sinai Hospital, Chicago; 2Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

Introduction: Several new medications are now available for immunosuppression in the kidney transplant field. Tacrolimus and mycophenolate mofetil were first introduced for ­immunosuppression in renal transplantation in the mid 1990s. Since then, the combination of tacrolimus and mycophenolate mofetil has been evaluated in numerous clinical trials. The outcomes of these trials have varied due to differences in induction and/or maintenance therapy, drug dosing and monitoring protocols, and study design. The aim of this review is to analyze the literature critically and to provide an overview of tacrolimus and mycophenolate mofetil combination therapy in renal transplantation.

Keywords: mycophenolate mofetil, tacrolimus, kidney transplantation, immunosuppression





 

Other articles by Dr Lorenzo Gallon

Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio